- BMO Capital ups its price target on Isis Pharmaceuticals (ISIS) to $43 from $31 after the company said over the weekend that its ISIS-APOC3-Rx treatment lowered triglyceride levels in three patients with familial chylomicronemia syndrome.
- BMO, which maintained its outperform rating, believes that the data demonstrates that ISIS-APOC3-Rx addresses a significant unmet need that could help accelerate the drug's time to market.
- Familial chylomicronemia syndrome is a rare and very serious genetic disorder that is characterized by high triglyceride levels. The condition causes problems such as abdominal pain, eruptive fatty skin lesions, enlargement of the liver and spleen, and recurrent acute pancreatitis
- Isis shares are +3.9% at $36.06.
BMO raises Isis' PT following positive drug results
Recommended For You
More Trending News
About IONS Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| IONS | - | - |
| Ionis Pharmaceuticals, Inc. | ||